![Håkan Rosén](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Håkan Rosén
Director/Board Member at Glucox Biotech AB
Net worth: 704 307 $ as of 31/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Per Ingvar Oskar Wikström | M | 70 |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | 21 years |
Johan Viberg | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Björn Karl-Axel Sundeby | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Alan Harris | M | - |
Glucox Biotech AB
![]() Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Sweden | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Håkan Rosén
- Personal Network